EUVIMEDEUVIMED entdecken
Open Access

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial

Glenn M Chertow iD, Ricardo Correa-Rotter, Priya Vart, Niels Jongs, John J V McMurray iD, Peter Rossing iD, Anna Maria Langkilde, C David Sjöström iD, Robert D Toto iD, David C Wheeler iD, Hiddo J L Heerspink iD, DAPA‐CKD Trial Committees and Investigators

Journal of the American Heart Association · 02.05.2023 · 12 (9)

DOI: 10.1161/jaha.122.028739 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 02.05.2023. Verfasst von Glenn M Chertow und 11 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Medicine, Epidemiology and Population Health, and Health Policy Stanford University School of Medicine Stanford CA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Kidney Failure, Chronic. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The DAPA‐CKD (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease) trial (NCT03036150) demonstrated that dapagliflozin reduced the risk of kidney and cardiovascular events in patients with chronic kidney disease and albuminuria with and without type 2 diabetes. We aimed to determine whether baseline cardiovascular medication use modified the dapagliflozin treatment effect. Methods and Results We randomized 4304 adults with baseline estimated glomerular filtration rate 25 to 75 mL/min per 1.73 m 2 and urinary albumin:creatinine ratio 200 to 5000 mg/g to dapagliflozin 10 mg or placebo once daily. The primary end point was a composite of ≥50% estimated glomerular filtration rate decline, end‐stage kidney disease, and kidney or cardiovascular death. Secondary end points included a kidney composite end point (primary composite end point without cardiovascular death), a cardiovascular composite end point (hospitalized heart failure or cardiovascular death), and all‐cause mortality. We categorized patients according to baseline cardiovascular medication use/nonuse. Patients were required by protocol to receive a stable (and maximally tolerated) dose of a renin‐angiotensin‐aldosterone system inhibitor. We observed consistent benefits of dapagliflozin relative to placebo, irrespective of baseline use/nonuse of renin‐angiotensin‐aldosterone system inhibitors (98.1%), calcium channel blockers (50.7%), β‐adrenergic antagonists (39.0%), diuretics (43.7%), and antithrombotic (47.4%), and lipid‐lowering (15.0%) agents. Use of these drugs in combination with dapagliflozin did not increase the number of serious adverse events.

Conclusions

The safety profile and efficacy of dapagliflozin on kidney and cardiovascular end points in patients with chronic kidney disease were consistent among patients treated and not treated at baseline with a range of cardiovascular medications. Registration Information clinicaltrials.gov . Identifier: NCT03036150.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Renal Insufficiency, ChronicKidney Failure, ChronicAdultHumansBenzhydryl CompoundsGlucosides

Stichwörter der Autor:innen

SGLT2 inhibitorscardiovascular medicationschronic kidney diseasedapagliflozin

Substanzen

Benzhydryl CompoundsdapagliflozinGlucosides

Autor:innen und Institutionen

  • Departments of Medicine, Epidemiology and Population Health, and Health Policy Stanford University School of Medicine Stanford CA.
  • Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City Mexico.
  • Department of Clinical Pharmacy and Pharmacology University of Groningen, University Medical Centre Groningen Groningen The Netherlands.
  • Institute of Cardiovascular and Medical Sciences University of Glasgow Glasgow UK.
  • Steno Diabetes Center Copenhagen Herlev Denmark.
  • Department of Clinical Medicine University of Copenhagen Copenhagen Denmark.

ORCID-Profile: Glenn M Chertow, John J V McMurray, Peter Rossing, C David Sjöström, Robert D Toto, David C Wheeler, Hiddo J L Heerspink

Zitieren

APA

Chertow, G. M., Correa-Rotter, R., Vart, P., Jongs, N., McMurray, J. J. V., Rossing, P., Langkilde, A. M., Sjöström, C. D., Toto, R. D., Wheeler, D. C., Heerspink, H. J. L., & DAPA‐CKD Trial Committees and Investigators (2023). Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial. Journal of the American Heart Association, 12(9). https://doi.org/10.1161/jaha.122.028739

Vancouver

Chertow GM, Correa-Rotter R, Vart P, Jongs N, McMurray JJV, Rossing P, et al. Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial. Journal of the American Heart Association. 2023;12(9). doi:10.1161/jaha.122.028739

BibTeX
@article{Chertow2023,
  author = {Chertow, Glenn M and Correa-Rotter, Ricardo and Vart, Priya and Jongs, Niels and McMurray, John J V and Rossing, Peter and Langkilde, Anna Maria and Sjöström, C David and Toto, Robert D and Wheeler, David C and Heerspink, Hiddo J L and DAPA‐CKD Trial Committees and Investigators, DAPA‐CKD Trial Committees and Investigators},
  title = {Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial},
  journal = {Journal of the American Heart Association},
  year = {2023},
  volume = {12},
  number = {9},
  doi = {10.1161/jaha.122.028739}
}
Kostenlos starten →